Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wisinski

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Physical Review Letters|August 6, 1990
Measurement of the absolute inclusive leptonic-decay branching fraction of the Ds+ mesonBai, Blaylock, Bolton, et al.
Nature Communications|October 14, 2025
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panelsKyle T Helzer, Marina N Sharifi, Jamie M Sperger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
JAMA Cardiology|May 27, 2021
Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac RegistryCurt J Daniels, Saurabh Rajpal, Joel T Greenshields, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
Contemporary Clinical Trials|May 4, 2024
Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trialK D Crew, G L Anderson, K B Arnold, et al.
BMC Medical Informatics and Decision Making|September 28, 2024
Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)Alissa M Michel, Haeseung Yi, Jacquelyn Amenta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2023
Fragmentomic analysis of circulating tumor DNA-targeted cancer panelsK T Helzer, M N Sharifi, J M Sperger, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Physical Review Letters|August 6, 1990
Measurement of the absolute inclusive leptonic-decay branching fraction of the Ds+ mesonBai, Blaylock, Bolton, et al.
Nature Communications|October 14, 2025
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panelsKyle T Helzer, Marina N Sharifi, Jamie M Sperger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid TumorsAtish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
JAMA Cardiology|May 27, 2021
Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac RegistryCurt J Daniels, Saurabh Rajpal, Joel T Greenshields, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
Contemporary Clinical Trials|May 4, 2024
Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trialK D Crew, G L Anderson, K B Arnold, et al.
BMC Medical Informatics and Decision Making|September 28, 2024
Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)Alissa M Michel, Haeseung Yi, Jacquelyn Amenta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2023
Fragmentomic analysis of circulating tumor DNA-targeted cancer panelsK T Helzer, M N Sharifi, J M Sperger, et al.
Pageof 14